If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article ...

Former Latham & Watkins global vice chair joins the firm as co-chair of its technology transactions practice | New partner ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The company’s nine-country ban against a Chinese rival saw the court adopt a broad interpretation of means-plus-function ...

In Wuhan Healthgen Biotech v ITC, the Federal Circuit affirmed the US International Trade Commission’s (ITC) conclusion that ...

British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent ...

5 March 2024 The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin ...

David Por joins the firm’s Paris team as partner | New hire brings two decades of experience, including in healthcare and ...

The former USPTO director has filed her first amicus brief since rejoining private practice, arguing that instructions issued ...

LSIPR sister title releases USA Patents Rankings, divided into categories of non-contentious and contentious work | Listing identifies the go-to firms and individuals for prosecution, litigation and ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.